#Israel #Caesarea #Cryoablation #ProSense® #IceCure

IceCure Medical's First Quarter Financial Highlights

IceCure Medical Ltd. (Nasdaq ICCM), a pioneer in minimally-invasive cryoablation technology, reported impressive financial performance for the first quarter of 2026, showcasing substantial growth in its flagship ProSense® product. The company announced a remarkable

46% surge in active customer accounts using ProSense® by March 31, 2026, attributed primarily to pent-up demand following recent FDA clearance. With this momentum, IceCure is poised for exciting advancements not only in the U.S. but across North America as well.

Strong Revenue Growth

In the first quarter of 2026, IceCure experienced a healthy 26% increase in global revenues, reaching $911,000 compared to $725,000 in the same period of 2025. Notably, sales in North America jumped by 84%, while U.S. sales rose by 31%. This growth reflects the expanding acceptance of ProSense® in treating early-stage breast cancer, driven by accumulated clinical data and heightened awareness amongst healthcare providers.

CEO Eyal Shamir expressed optimism regarding the company’s trajectory, stating, "We are off to an incredibly strong start to 2026 and are very encouraged by the growing momentum we are experiencing in the U.S. for ProSense® in early-stage breast cancer."

Expanding Commercial Footprint

Following FDA clearance, IceCure has swiftly broadened its commercial footprint, introducing proSense® installations in key locations, such as Thomas Hospital in Alabama and SHERO Imaging in Missouri, the first institutions in their respective areas to provide breast cancer cryoablation. The company is also capitalizing on its presence at significant industry conferences; their promotion of ProSense® at the American Society of Breast Surgeons 2026 Annual Meeting notably featured a symposium titled "Unlocking De-Escalation Cryoablation for Breast Cancer."

The company is actively working to convert its growing pipeline of hospitals and clinics into revenue, thus expanding interest and market penetration across eight regions in the U.S.

Clinical and Marketing Advances

Additionally, IceCure is advancing their post-marketing ChoICE study participating 30 hybrid clinical-commercial sites in the U.S. The study has achieved FDA approval and is expected to further drive ProSense® adoption by demonstrating efficacy and supporting a broader reimbursement framework.

The American Society of Breast Surgeons has also updated its guidelines, recommending cryoablation as a local treatment option for low-risk breast cancer—a notable shift that underscores the increasing acceptance of IceCure’s technology.

Financial Overview

Despite the promising growth, IceCure faced a net loss of $4.274 million in the first quarter of 2026, slightly more than the previous year's loss of $3.588 million. The increase in losses can be largely attributed to higher research and development costs, which rose to $2.211 million, as the company continues to invest heavily in its innovative products and studies.

However, IceCure appears to be well-positioned to tackle these challenges moving forward. With $8.115 million in cash and cash equivalents as of March 31, 2026, they maintain a solid financial foundation to support ongoing operations and expansion efforts.

In conclusion, IceCure Medical's official report indicates a robust growth trajectory propelled by the ProSense® system. Their strategic initiatives post-FDA clearance and continual investment in clinical trials and marketing campaigns reinstate their commitment to transforming breast cancer treatment while ensuring safety and efficacy. As they expand their reach and fortify their partnerships, IceCure is poised for even greater achievements in the medical technology sphere.

• ---